IGF-1 LR3

IGF-1 LR3 Regulatory Status

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

IGF-1 LR3 holds no marketing authorisation from the MHRA, EMA or FDA. A licensed recombinant human IGF-1 does exist (mecasermin, marketed as Increlex), but that is native rhIGF-1, a different molecule, and its approval extends to LR3 in no respect.

Key facts

MHRA status
Not authorised
EMA status
Not authorised
FDA status
Not approved
Approved related product
Mecasermin (Increlex), native rhIGF-1
WADA
Prohibited at all times, class S2
Supply basis here
Laboratory research only

The position

No regulator has assessed IGF-1 LR3. There is no marketing authorisation anywhere, no registered clinical trial programme, and no route by which a laboratory reagent becomes a medicine. It is supplied for laboratory research only.

The complication unique to this category

An approved IGF-1 medicine exists. Mecasermin, marketed as Increlex, is recombinant human IGF-1 with an FDA label and a subcutaneous route, used in severe primary IGF-1 deficiency. That is a real licensed product with real clinical evidence behind it; Petriczko 2019 and Denaite 2024 both report on its use.

Research material referenced

IGF-1 LR3 1mg, third-party HPLC tested

Buy IGF-1 LR3 · £49.99

Why that makes things riskier rather than safer

A nearby approval invites the inference that the unapproved analogue is somehow covered by it. It is not. The approved product is the native 70-residue hormone; LR3 is an 83-residue engineered analogue with deliberately altered binding behaviour. Sharing a family name is the entire extent of the relationship, and treating the approval as transferable is the most consequential error available here.

The prohibited status runs alongside

IGF-1 and its analogues sit in WADA class S2, prohibited at all times. That applies regardless of regulatory status and regardless of whether material is described as being for research.

What is said here

That IGF-1 LR3 is an 83-residue recombinant analogue engineered to reduce IGF binding protein affinity, developed as a cell culture reagent, with almost no primary literature under that name. Not said: that it does anything in any person, or that anything about mecasermin's approval applies to it.

The enforcement context

The MHRA opened investigations into UK retailers making therapeutic claims about unregulated products in April 2026. For a compound that is both unlicensed and prohibited in sport, with an approved relative to be confused with, the margin for imprecise language is narrower here than anywhere else in this catalogue.

Frequently asked questions

Is IGF-1 LR3 approved anywhere?

No. It holds no marketing authorisation from any regulator.

But isn't there an approved IGF-1 product?

Yes: mecasermin, marketed as Increlex. That is native rhIGF-1, a different molecule, and its approval does not extend to LR3.

Does research use change the prohibited status?

No. WADA class S2 applies at all times regardless of how material is described or supplied.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More IGF-1 LR3 articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.